• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 115
  • 50
  • 39
  • 20
  • 10
  • 8
  • 5
  • 4
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • Tagged with
  • 268
  • 176
  • 114
  • 82
  • 68
  • 64
  • 63
  • 59
  • 48
  • 40
  • 33
  • 30
  • 29
  • 27
  • 26
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
101

Inflammatory bowel disease in twins : studies of genetics and environmental factors /

Halfvarson, Jonas, January 2005 (has links) (PDF)
Diss. Linköping : Linköpings universitet, 2005.
102

Les associations potentielles de gènes KIR avec la susceptibilité/résistance au développement de la maladie de Crohn

Samarani, Suzanne 12 1900 (has links)
No description available.
103

Estudo do modelo de inflamação intestinal induzida por TNBS em larvas de Zebrafish (Danio rerio). / Study of the intestinal inflammation model induced by TNBS in Zebrafish larvae (Danio rerio).

Fenero, Camila Ideli Morales 13 August 2015 (has links)
As doenças inflamatórias intestinais são caracterizadas por uma desregulação na resposta imune contra a microbiota. O zebrafish, tem emergido como um novo modelo para o estudo de doenças inflamatórias. Os ácidos graxos de cadeia curta (AGCCs) são produtos da microbiota intestinal, que possuem papéis antiinflamatórios e aparecem como uma das possíveis terapias contra doenças inflamatórias. A implementação do modelo de inflamação intestinal induzido pelo ácido trinitrobenzenesulfônico (TNBS) em larvas de zebrafish aumentou a mortalidade de forma dose-dependente. Se observou dilatação do lúmen com alisamento das vilosidades intestinais. Não se detectaram mudanças na produção de muco nem no número de células caliciformes mas teve um leve aumento da apoptóse e diminuição da proliferação, nos expostos ao TNBS. Teve aumento de células mielóides infiltrantes e de citocinas inflamatórias, assim como disbiose da microbiota. O tratamento com AGCCs gero alta mortalidade a concentrações acima de 10 mM, mas existe ação anti-inflamatória a esta mesma concentração. / Inflammatory bowel diseases are characterized by a dysregulation in immune response against microbiota. The zebrafish has emerged as a new model for the study of inflammatory diseases. Short chain fatty acids (SCFAs) are products of the intestinal microflora, which have anti-inflammatory roles and appear as a possible therapy against inflammatory diseases. The implementation of intestinal inflammation model induced by trinitrobencenesulfonic acid (TNBS) in zebrafish larvae, increased mortality in a dose-dependent manner. Was observe dilatation lumen and straightening of the intestinal villi. No changes were detected in the production of mucus or in the number of goblet cells but had a slight increase in apoptosis and decreased proliferation in exposed to TNBS. Also has, increased cytokines and infiltrating myeloid cells, and dysbiosis of the microbiota. Treatment with SCFAs generate high mortality above 10 mM concentrations, but there anti-inflammatory action to this same concentration.
104

Manifestações orais da doença inflamatória intestinal: estudo clínico-patológico retrospectivo / Oral manifestations of inflammatory bowel disease: retrospective clinical-pathologic study

Pincelli, Thaís Prota Hussein 12 May 2010 (has links)
O termo doença inflamatória intestinal engloba duas doenças inflamatórias crônicas, imunologicamente mediadas, envolvendo o trato gastrointestinal: a doença de Crohn e a retocolite ulcerativa. Os sintomas intestinais são predominantes, porém, durante o curso da doença, podem ocorrer manifestações extraintestinais, incluindo o envolvimento da cavidade oral. O envolvimento oral na doença inflamatória intestinal pode se dar por diferentes tipos de lesões, sendo o tipo mais comum a afta. Lesões menos frequentes incluem, entre outras, a pioestomatite vegetante e as lesões granulomatosas da doença de Crohn. Apresentamos dez casos de doentes com manifestações orais de doença inflamatória intestinal, sendo que, em alguns desses casos, essas foram essenciais para o diagnóstico definitivo da doença, além de revisão detalhada da literatura. O envolvimento da cavidade oral pode ser prévio ou simultâneo aos sintomas gastrointestinais. Porém, na maior parte dos casos, a doença inflamatória intestinal precede o início das lesões orais em meses ou anos. Em muitos doentes, a sintomatologia intestinal pode ser mínima ou mesmo ausente, o que justifica exame minucioso do trato gastrointestinal em todos os doentes com lesões orais suspeitas, mesmo na ausência de sintomas evidentes. Geralmente, o curso clínico das lesões orais é paralelo à atividade da doença inflamatória intestinal, por isso as manifestações orais são consideradas bons marcadores cutâneos da doença / Inflammatory bowel disease comprises two chronic, tissue-destructive, clinical entities: Crohns disease and ulcerative colitis, both immunologically based. Bowel symptoms are predominant, but extra-intestinal complications may occur, including involvement of the oral cavity. Oral involvement during Inflammatory bowel disease includes several types of lesions: the most common are aphthae; uncommon lesions include, among others, pyostomatitis vegetans and granulomatous lesions of Crohns disease. Starting with a presentation of ten patients with oral manifestations, which were crucial for the final diagnosis of inflammatory bowel disease, a review on the subject is presented. Oral involvement in inflammatory bowel disease may be previous or simultaneous to the gastrointestinal symptoms. However, in the majority of cases, bowel disease precedes the onset of oral lesions by months or years. In many patients, the intestinal symptoms may be minimal and can go undetected; thus, most authors believe that the bowel must be thoroughly examined in all patients with suspected inflammatory bowel disease even in the absence of specific symptoms. Usually, the clinical course of oral lesions is parallel to the activity of inflammatory bowel disease; therefore, oral manifestations are a good cutaneous marker of inflammatory bowel disease
105

Tratamento cirúrgico da doença de Crohn:estudo comparativo entre desfechos precoses após laparoscopia primária, laparoscopia repetida ou laparoscopia após laparotomia na recidiva / Surgical treatment of Crohn\'s Disease: a comparative study between short-term outcomes after primary laparoscopy, repeated laparoscopy or laparoscopy after laparotomy for recurrent disease

Araújo, Marleny Novaes Figueiredo de 17 February 2017 (has links)
Introdução: o uso da videolaparoscopia na doença de Crohn (DC) teve seu início nos anos 90, com ressalvas à possível dificuldade técnica que a DC complexa ou recorrente poderia impor à sua realização. Diversos estudos ao longo das décadas de 90 e 2000 mostraram ser a mesma factível, quando comparada à laparoscopia para DC primária, além de demonstrarem maior benefício da laparoscopia comparada à cirurgia aberta/convencional nos casos de DC recorrente. Entretanto, não houve estudos sobre resultados cirúrgicos após repetidas ressecções laparoscópicas. Objetivo: avaliar resultados pós-operatórios em curto prazo no tratamento da DC, comparando pacientes submetidos a uma segunda ressecção intestinal laparoscópica e pacientes sem cirurgia prévia. Além disso, comparar os mesmos resultados pós-operatórios entre pacientes submetidos a uma segunda ressecção intestinal laparoscópica e pacientes sendo submetidos a laparoscopia para DC e história prévia de ressecção intestinal prévia por laparotomia. Materiais e métodos: foi realizado análise retrospectiva a partir de base de dados mantida prospectivamente de pacientes submetidos a laparoscopia para tratamento da DC no Hospital Beaujon, França, entre 2005 e 2010. Os desfechos analisados foram: conversão para cirurgia aberta, tempo operatório, taxa de enterotomias inadvertidas no intra-operatório, morbidade, necessidade de reintervenção (cirúrgica ou radiológica) e tempo total de hospitalização. Resultados: foram analisados 18 pacientes com laparoscopia prévia (grupo A), 90 pacientes sem cirurgia prévia (grupo B) e 26 pacientes com laparotomia prévia (grupo C). Em nossa análise principal, comparando os grupos A e B, vemos grupos semelhantes em relação a dados demográficos, exceto maior número de casos complexos no grupo A (83,3 vs 46,7%; p=0,005) e tipo de operação realizada (p < 0,001). Quanto aos resultados, apenas o tempo operatório foi significativamente mais longo no grupo A (180 minutos vs. 150 minutos; p=0,013). A taxa de conversão, enterotomia inadvertida, morbidade, necessidade de reintervenção e tempo de hospitalização foram similares entre os grupos. Em nossa segunda análise, entre os grupos A e C, não houve diferença significativa quanto aos mesmos resultados analisados. Conclusão: apesar de um maior tempo operatório, uma segunda ressecção laparoscópica mantém os mesmos benefícios vistos em uma ressecção intestinal laparoscópica primária. Os mesmos benefícios são vistos quando os resultados são comparados com pacientes submetidos previamente a uma ressecção intestinal por laparotomia, em especial quando nas mãos de equipe experiente / Introduction: the use of laparoscopy in Crohn\'s disease (CD) had its beginning in the 90s, despite the possible challenge of technical difficulty that the complex or recurrent CD could impose to its realization. Numerous studies over the decades of 90 and 2000 showed laparoscopy in recurrent CD to be feasible compared to laparoscopy for primary CD, and have also shown the benefits of laparoscopic compared to open conventional surgery in patients with recurrent CD. However, there were no studies on surgical outcomes after repeated laparoscopic resections. Objective: 1. to evaluate postoperative short-term results regarding surgical treatment of CD, comparing patients who underwent a second laparoscopic bowel resection and patients without prior surgery. 2. to compare the same postoperative results among patients who underwent a second laparoscopic bowel resection patients and patients undergoing laparoscopic resection with history of prior intestinal resection by laparotomy. Materials and methods: a retrospective analysis from prospectively maintained database of patients undergoing laparoscopy for treatment of CD in Hospital Beaujon, France, between 2005 and 2010, was performed. The outcomes analyzed were: conversion to open surgery, operative time, intraoperative inadvertent enterotomy, morbidity, need for re-intervention (surgical or radiological) and length of hospitalization. Results: 18 patients with previous laparoscopy (group A), 90 patients without previous surgery (group B) and 26 patients with previous laparotomy (group C) were included. In our main analysis, comparing the groups A and B, groups were similar in respect to demographic data, except number of complex cases in group A (83.3 vs 46.7%; p = 0.005) and type of surgery performed (p < 0.001). As for the results, operative time was significantly longer in group A (180 minutes vs. 150 minutes; p = 0.013). Conversion rate, inadvertent enterotomy, morbidity, need for re-intervention and hospital stay were similar between groups. In our second analysis, between groups A and C, there was no significant difference between groups regarding the same variables. Conclusion. In spite of a longer operative time, a second laparoscopic resection guarantees the same benefits seen in a primary laparoscopic bowel resection. The same benefits are kept compared to patients who underwent prior bowel resection by laparotomy, especially when in the hands of experienced staff
106

"Investigação sobre a adesão ao tratamento medicamentoso em pacientes com doenças inflamatórias intestinais" / Investigation on compliance to drug therapy in patients with inflammatory bowel diseases.

Dewulf, Nathalie de Lourdes Souza 02 December 2005 (has links)
A adesão ao tratamento medicamentoso é um importante fator determinante no sucesso terapêutico. A adesão do paciente pode ser influenciada por fatores diversos, ligados à doença, ao tratamento, ao paciente, às condições sociais e econômicas, como também, relacionada ao sistema de saúde que o atende. Ainda que existam inúmeros estudos sobre a adesão ao tratamento em portadores com doenças crônicas, são escassas as investigações sobre este tema nas doenças inflamatórias intestinais. O presente trabalho teve o objetivo de avaliar a adesão ao tratamento medicamentoso e os possíveis fatores que a influenciam, em pacientes portadores de doenças inflamatórias intestinais (DII): doença de Crohn (DC) e retocolite ulcerativa (RCU), do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto (HCFMRP), da Universidade de São Paulo. Como controles, foram investigados pacientes portadores de pancreatite crônica e insuficiência pancreática (PC), com medicação fornecida pelo hospital, tal como os pacientes portadores de DII. Foram também investigados pacientes portadores de afecções digestivas variadas (ADV), grupo no qual a medicação prescrita não era fornecida pelo hospital. Por meio de estudo transversal e indireto, foi realizada entrevista estruturada para avaliar a adesão de 110 pacientes, que foram caracterizados como apresentando maior ou menor grau de adesão. Esta classificação foi baseada no cotejo entre os dados do prontuário e os informados pelo paciente em entrevista, considerando a afirmação do paciente que usava a medicação e que conhecia o nome da droga em uso. Utilizou-se, também, o teste de Morisky, que permite avaliar o padrão de comportamento do paciente em relação ao uso diário do medicamento. Este teste consiste de quatro perguntas padronizadas relacionadas ao esquecimento, descuido com o horário de tomada do medicamento, percepção de efeitos colaterais e ausência de sintomas. Na análise dos medicamentos utilizados pelo paciente, foram observadas as seguintes proporções de pacientes classificados como menos aderentes: 15,4% em pacientes portadores de DC, 13,3% na RCU, 8,4% na PC e 16,6% nos pacientes do grupo ADV. Porém, o teste de Morisky mostrou as seguintes proporções de menos aderentes: 50% de pacientes portadores de DC, 63,3% na RCU, 54,2% na PC e 63,4% na ADV. Não houve diferenças estatisticamente significativas, entre os grupos de pacientes, tanto na análise dos medicamentos utilizados pelo paciente como pelos resultados do teste de Morisky. Em análise univariada, nenhum dos fatores demográficos, sociais, clínicos ou referentes ao tratamento medicamentoso apresentou relação estatisticamente significativa, comum a todos os grupos, que indicasse influência sobre a adesão ao tratamento. Apesar do alto grau de adesão, de acordo com a análise dos medicamentos utilizados, detectou-se alto percentual de não-adesão ao tratamento medicamentoso ligado ao comportamento habitual e independente do diagnóstico, ou do acesso gratuito aos medicamentos. Isto pode indicar a existência de um padrão específico de comportamento dos usuários do serviço, o que sugere a necessidade de maior atenção dos profissionais de saúde para o problema, bem como medidas de educação do paciente quanto ao uso dos medicamentos. / Compliance to drug therapy is an important factor determining a successful treatment. Patient compliance may be influenced by various factors related to the disease, to treatment, to the patient himself, to his socioeconomic condition, as well as to the health system. Although many studies have assessed compliance to treatment in patients with chronic diseases, few investigations are available in inflammatory bowel diseases (IBD). The objective of the present study was to assess compliance to drug therapy in patients with IBD - Crohn’s disease (CD) and ulcerative colitis (UC), seen at the University Hospital, Faculty of Medicine of Ribeirão Preto (HCFMRP), University of São Paulo, Brazil. Patients with chronic pancreatitis (CP) and pancreatic insufficiency who received free medication supplied by the hospital, like the IBD patients, were used as controls. Patients with various digestive affections (VDA) whose prescribed medication was not supplied by the hospital were also investigated. In a transverse and indirect study, a structured interview was applied to assess the compliance of 110 patients, who were characterized as presenting a higher or lower degree of compliance. This classification was based on a comparison of data in the medical records to the information provided by the patient in the interview, considering the patient’s statements that he/she actually used the medication and was capable of produce correctly its name. The Morisky test was also used to assess the behavioral pattern of the patient regarding the daily use of the medication. This test consists of four standardized questions that evaluate forgetfulness, carelessness regarding the time when the medication should be taken, the perception of side effects, and the absence of symptoms. In the analysis of patient statements on medication in use, the proportions of patients regarded as less compliant were as follows: 15.4% of patients with CD, 13.3% of those with UC, 8.4% of those with CP, and 16.6% of those with VDA. However, the Morisky test revealed the following proportions of less compliant patients: 50% of patients with CD, 63.3% of those with UC, 54.2% of those with CP, and 63.4% of those with VDA. No statistically significant differences were observed between the four groups regarding evaluation according to either the analysis of patient statements or the results of the Morisky test. Univariate analysis revealed that none of the demographic, social, or clinical factors or the variables related to drug therapy showed statistically significant relationships, common to all groups, that would indicate their influence on compliance to treatment. Despite the high degree of compliance evaluated by patient statements on medication in use, a high degree of noncompliance to treatment linked to habitual behavior was detected. Those findings were independent on either disease type or free access to medication. This may indicate the existence of a specific behavioral pattern common to the local health system users, which suggests the need for better consideration of the problem on the part of the health professionals, as well as the need for measures of patient education regarding medication use.
107

Implication des exosomes et de l'autophagie dans l'interaction entre l'hôte et les Escherichia coli adhérents et invasifs associés à la maladie de Crohn. / Implication of exosomes and autophagy in the interaction between host and adherent and invasive Escherichia coli associated with Crohn's disease.

Carriere, Jessica 25 November 2015 (has links)
La maladie de Crohn (MC) est une maladie inflammatoire chronique du tube digestif caractérisée par un état d’hyperactivation du système immunitaire intestinal. L’étiologie de cette maladie est encore mal connue mais les données cliniques et expérimentales montrent que l’étiologie de la MC fait intervenir des facteurs environnementaux, génétiques et infectieux entraînant une réponse immunitaire aberrante. A ce jour, aucun traitement spécifique n’est disponible et la MC représente un problème majeur de santé publique de par ses conséquences invalidantes, sa nature chronique et récidivante, et sa prévalence croissante. Plusieurs groupes dont le nôtre ont rapporté une colonisation anormale de la muqueuse intestinale des patients atteints de MC par des souches de E. coli adhérentes et invasives dénommées AIEC. La caractérisation des souches AIEC a montré qu’elles sont capables d’adhérer et d’envahir des cellules épithéliales intestinales, de survivre et se multiplier dans des macrophages et d’induire une forte réponse pro-inflammatoire. Des études récentes ont montré que l’autophagie est induite dans les cellules hôtes en réponse à l’infection par les AIEC afin de contrôler la réplication intracellulaire des AIEC.Les travaux menés au cours de cette thèse visent à étudier les mechanismes moleculaires impliqués dans l’interaction entre l’hôte et les AIEC avec 2 objectifs principaux : (i) étudier l’implication des exosomes dans les interactions hôte/AIEC, (ii) étudier l’implication de la voie de signalisation GCN2/eIF2α/ATF4 dans la réponse autophagique à l’infection par les AIEC. Concernant le premier axe de recherche, les résultats ont permis de mettre en lumière une fonction jusque-là inconnue des exosomes dans la communication cellule à cellule au cours des réponses de l’hôte à l’infection par les AIEC. Ainsi, nous avons mis en évidence que les exosomes sont impliqués à la fois dans la réplication intracellulaire des AIEC et dans les réponses immunitaires innées des cellules hôtes à l’infection. Les résultats du deuxième axe de recherche ont permis de révéler un rôle essentiel de la voie de signalisation GCN2/eIF2α/ATF4 dans la réponse autophagique de l’hôte à l’infection par les AIEC associés à la MC. Nous avons démontré que l’infection par les souches AIEC conduit à l’activation de cette voie de signalisation, entraînant la mise en place d’une machinerie autophagique efficace pour contrôler la réplication intracellulaire des AIEC et inhiber l’inflammation. / Crohn's disease (CD) is a chronic inflammatory disease of the digestive tract characterized by a state of hyperactivation of the intestinal immune system. The etiology of this disease is still poorly understood, but clinical and experimental data show that the etiology of CD involves environmental, genetic and infectious factors leading to an aberrant immune response. To date, no specific treatment is available and CD represents a major public health problem due to its disabling consequences, its chronic and recurrent nature, and its increasing prevalence. Several groups, including ours, have reported abnormal colonization of the intestinal mucosa of CD patients with adherent and invasive E. coli strains called AIEC. The characterization of AIEC strains has shown that they are able to adhere and invade intestinal epithelial cells, survive and multiply in macrophages and induce a strong pro-inflammatory response. Recent studies have shown that autophagy is induced in host cells in response to AIEC infection in order to control the intracellular replication of AIEC. The work conducted during this thesis aims to investigate the molecular mechanisms involved in interaction between host and AIEC with 2 main objectives: (i) to study the involvement of exosomes in host / AIEC interactions, (ii) to study the involvement of the GCN2 / eIF2α / ATF4 signaling pathway in the response autophagic to infection with AIEC. With regard to the first line of research, the results shed light on a hitherto unknown function of exosomes in cell-to-cell communication during host responses to AIEC infection. Thus, we have shown that exosomes are involved in both intracellular replication of AIECs and innate immune responses of host cells to infection. The results of the second line of research revealed a critical role for the GCN2 / eIF2α / ATF4 signaling pathway in the host autophagic response to AIEC infection associated with CD. We have shown that infection with AIEC strains leads to activation of this signaling pathway, leading to the establishment of autophagic machinery that is effective in controlling intracellular replication of AIEC and inhibiting inflammation.
108

Eficàcia dels tocotrienols com a estratègia de tractament de la fibrosi intestinal

Luna Cornadó, Jeroni 31 October 2011 (has links)
En el patró fibroestenosant de la malaltia de Crohn els fibroblasts intestinals augmenten en número contribuint al desenvolupament de la fibrosi. Un dels principals promotors de la proliferació d’aquestes cèl•lules és el bFGF. En el present estudi la fracció rica en tocotrienol ha demostrat tenir efectes antiproliferatius en fibroblasts intestinals humans independentment de la procedència dels fibroblasts. Els tocotrienols redueixen tant la proliferació basal com la induïda per bFGF en fibroblasts. L’apoptosi de les cèl•lules efectores en el desenvolupament de la fibrosi sembla ser el principal mecanisme de la seva resolució. Els tocotrienols instauraren un procés complert d’apoptosi en els fibroblasts. A diferència del que passa amb la majoria d’agents proapoptòtics, els tocotrienols provoquen l’activació tant de la via extrínseca com de la via intrínseca de l’apoptosi ja que activa les caspases 8 i 9. Sorprenentment, l’addició de ciclosporina A (CsA), un conegut inhibidor de la via intrínseca de l’apoptosi, bloqueja completament el procés d’apoptosi induït per FRT. Això demostra que tot i l’activació de la caspasa 8 i per tant, de la via extrínseca, en el tractament amb tocotrienols la predominant és la via intrínseca. L’autofàgia té un paper molt rellevant en l’aclariment de cossos apoptòtics. Els tocotrienols han demostrat eficàcia en la inducció d’autofàgia en fibroblasts, ja que provoca la maduració de la proteïna LC3 i l’aparició de vacuoles autofàgiques en el citoplasma d’aquestes cèl•lules. Un cop més la CsA reverteix aquest procés, i per tant inhibeix l’autofàgia, demostrant que aquest procés requereix la participació de la mitocòndria. Les patologies que cursen amb desenvolupament de fibrosi estan associades a alts nivells de TGF-β que resulta en el reclutament de fibroblasts al lloc de la lesió i a un increment en la producció de matriu extracel•lular. A nivell intracel•lular, la fosforilació d’Smad3 és el pas clau que regula les accions del TGF-β. Els tocotrienols han mostrat eficàcia en la disminució dels nivells intracel•lulars d’Smad3 fosforilada induïda per TGF-β. La fosforilació d’Smad3 té efectes oposats en la regulació de l’expressió gènica. Regula positivament l’expressió de TIMP-1, en canvi, regula negativament l’expressió de MMP-3. Tot i ser efectes oposats en quant a expressió gènica, aquests dos fenòmens afavoreixen l’acumulació de matriu extracel•lular. L’exposició a tocotrienols fa que es reverteixi aquest estat profibrogènic ja que indueix l’expressió de MMP-3 però no afecta als nivells de TIMP-1. La síntesi de MEC i especialment la síntesi de COL1, COL3 i COL5 està incrementada en la fibrosi intestinal, aquest fet està directament relacionat amb l’activitat de TGF-β en la zona afectada. Els tocotrienols interfereixen en la síntesi de col•lagen. A més, els tocotrienols disminueixen la fosforilació d’Smad3 induïda per TGF-β, un fet clau en la síntesi de matriu extracel•lular. Aquests resultats permeten hipotetitzar un potencial antifibrogènic dels tocotrienols. Per a confirmar aquest potencial “in vivo” ens calia disposar d’un model experimental de fibrosi intestinal. A diferència del que succeeix amb la colitis, en la que es disposa d’un gran nombre de models animals, hi ha pocs models experimentals específicament dissenyats per a reproduir la fibrosi intestinal. Aquest fet, ha limitat molt el desenvolupament de noves estratègies de tractament antifibrogènic en l’intestí. Mitjançant l’administració intracolònica repetida a dosis baixes de l’haptè TNBS vam poder establir fibrosi intestinal en la rata de manera rellevant i reproduïble. En aquest model de fibrosi intestinal, els animals que van rebre la dosi més alta de tocotrienols provada en aquest estudi van mostrar nivells disminuïts en paràmetres que mesuren la inflamació, això és, es va disminuir l’índex d’activitat de la malaltia i la pèrdua de pes causada pel TNBS així com també va reduir l’expressió de TNF-α. / Excessive fibroblast expansion and extracellular matrix deposition are key events for the development of bowel stenosis in Crohn’s disease patients. Tocotrienols are vitamin E compounds with proven in vitro antifibrogenic effects on rat pancreatic fibroblasts. We aimed at investigating the effects of tocotrienols on human intestinal fibroblast proliferation, apoptosis, autophagy, and synthesis of ECM. Intestinal fibroblasts isolated from patients with Crohn’s disease were treated with tocotrienol-rich fraction from palm oil. Tocotrienols significantly reduced proliferation, enhanced cell death by promoting apoptosis and autophagy. Fibroblast apoptosis, but not autophagy, was prevented by the pan-caspase inhibitor zVAD-fmk, whereas both types of cell death were prevented when the mitochondrial permeability transition pore was blocked by cyclosporin A, demonstrating a key role of the mitochondria in these processes. TRF diminished procollagen type I and laminin γ production these cells. Transforming growth factor-β plays a key role in matrix deposition during fibrosis. Treatment of intestinal fibroblasts with tocotrienol rich fraction prevents Smad3 phosporylation induced by transforming growth factor-β and reduces collagen type 1 and 3 production by these cells. Besides, in a rat model of intestinal fibrosis, treatment with tocotrienols reduces diarrhea, rectal bleeding and weight loss, as well as levels of colonic tumor necrosis factor-α and vimentin expression demonstrating that this compound has anti-inflammatory effects in vivo.
109

Malignant transformation of the colorectal mucosa in inflammatory bowel disease /

Sjöqvist, Urban, January 2003 (has links)
Diss. (sammanfattning) Stockholm : Karol. inst., 2003. / Härtill 5 uppsatser.
110

Nitric oxide : a surrogate marker of bowel inflammation /

Reinders, Claudia I., January 2005 (has links)
Diss. (sammanfattning) Stockholm : Karol. inst., 2005. / Härtill 4 uppsatser.

Page generated in 0.0522 seconds